Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.15
+0.15 (3.00%)
At close: Jul 25, 2025, 4:00 PM
5.16
+0.01 (0.19%)
After-hours: Jul 25, 2025, 7:29 PM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $29.00K in the quarter ending March 31, 2025, a decrease of -99.84%. This brings the company's revenue in the last twelve months to $51.14M, down -11.11% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$51.14M
Revenue Growth
-11.11%
P/S Ratio
0.79
Revenue / Employee
$473,528
Employees
108
Market Cap
57.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DTIL News
- 3 days ago - Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
- 10 days ago - Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
- 4 weeks ago - Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
- 2 months ago - Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire
- 2 months ago - Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - Business Wire
- 2 months ago - Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - Business Wire
- 3 months ago - Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire